Celerion Named Best Translational Clinical Pharmacology Company 2016
Lincoln, NE (October 5, 2016) — Celerion is pleased to announce that it is the recipient of the 2016 International Life Sciences Award in the Best Translational Clinical Pharmacology Company category. The awards panels evaluated global nominees over a wide range of parameters including leadership in innovation, excellence in products and services, success stories and client testimonials. The results have been published in GHP’s 2016 International Life Science Awards Winners’ Supplement.
Celerion Translates Science into Medicine, using state of the art technologies and new, innovative approaches in early clinical research. Serving clients of all sizes in the pharmaceutical and biotechnology industries, Celerion focuses on clinical pharmacology Phase I and IIa trials.
Translational medicine, where evaluation of drug safety, tolerability and efficacy is assessed for the first time in humans, represents the cutting edge of pharmaceutical science. Celerion invests in and applies targeted technologies to support our clients’ need for greater clarity earlier in the drug development process.
“This award highlights the innovation and commitment of Celerion to support clients’ evolving needs,” said Susan Thornton, President and CEO. “Our highly experienced team, consulting expertise, robust technologies and methodologies enable us to enhance efficiency, precision and reduce costs, helping clients get their products to the marker faster.”
Translating science into medicine, Celerion is a premier provider of translational clinical pharmacology sciences from their global locations including North America, Europe and Asia.
Celerion conducts first-in-human, clinical proof of concept and patient dose response studies, cardiovascular safety and NDA-enabling clinical pharmacology research. Celerion provides full study services including statistics, data management and biostatistics (including PK/PD analysis), and bioanalytical services. www.celerion.com
Lorraine M. Rusch, Ph.D
Vice-President, Commercial Development